Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Stock

September 0	4, 2008									
FORM 4 UNITED STATES SECURITIES AND EVCHANCE COMMISSION								OMB APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287	
Check th if no long	is box							Expires:	January 31, 2005	
subject to Section 1 Form 4 c	51A1EN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES						Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Responses)										
1. Name and A BOGER JO	Address of Reporting SHUA S	Symbol	2. Issuer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
			EX PHAR MA [VRT		TICA	ALS	(Check all applicable)			
			Date of Earliest Transaction Month/Day/Year)				X Director 10% Owner X Officer (give title Other (specify below)			
C/O VERTI		09/03/	2008					below) esident & CEO		
	CEUTICALS RATED, 130 WA	VERLY								
INCORPORATED, 130 WAVERLY STREET										
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)				
X Form filed by One Reporting Person Form filed by More than One Reporting Form filed by More than One Reporting										
(City)	(State)	(Zip) Tal		·		.,.	Person	D 6 11		
		- 14)				-	uired, Disposed of			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	09/03/2008		M	12,400	A	\$ 10.19	1,107,444	D		
Common Stock	09/03/2008		S <u>(1)</u>	12,400	D	\$ 25.93 (2) (3)	1,095,044	D		

401(k)

Shares in

12,445

207,500

I

I

Stock trust (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of actionDerivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 10.19	09/03/2008		M		12,400	(5)	09/16/2008	Common Stock	12,400

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Numer / Mules	Director	10% Owner	Officer	Other		
BOGER JOSHUA S						
C/O VERTEX PHARMACEUTICALS INCORPORATED	v		President			
130 WAVERLY STREET	X		& CEO			
CAMBRIDGE, MA 02139						

Signatures

Valerie L. Andrews, Attorney-In-Fact 09/04/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$25.93 (range \$25.47 to \$26.43).
- (3) Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

Reporting Owners 2

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

(5) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.